Topics
Latest
AI
Amazon
Image Credits:Oregon State University /Flickr(opens in a new window)under aCC BY-SA 2.0(opens in a new window)license.
Apps
Biotech & Health
Climate
Image Credits:Oregon State University /Flickr(opens in a new window)under aCC BY-SA 2.0(opens in a new window)license.
Cloud Computing
Commerce
Crypto
endeavor
EVs
Fintech
Fundraising
gadget
game
Government & Policy
Hardware
Layoffs
Media & Entertainment
Meta
Microsoft
secrecy
Robotics
protection
societal
Space
startup
TikTok
Transportation
speculation
More from TechCrunch
Events
Startup Battlefield
StrictlyVC
Podcasts
telecasting
Partner Content
TechCrunch Brand Studio
Crunchboard
get hold of Us
Rather than grimly assembling data about cancer end to prefigure upshot in handling , the laminitis of Cure51 had another idea : rather , the company piece data about long - terminal figure survivor of Cancer the Crab , hoping to break through the code on what hold open people animated .
The troupe has now elicit a € 15 million seed circle lead by Paris - based Sofinnova Partners . Other investor in the round include Hitachi Ventures GmbH , Life Extension Ventures , Xavier Niel and Olivier Pomel , the CEO and co - laminitis of Datadog .
Cure51 will now use the money to establish a “ age bracket ” of datum to work out why certain cancer patient role pull through for a long time , even with highly fast-growing human body of the disease .
Cure51 was launch in March 2022 by Nicolas Wolikow and Simon Istolainen . Wolikow formerly founded healthtech startup Qare , and Istolainen has previously been an investor and adviser in healthcare .
Wolikow told me : “ There are plenty of caller licensing oncology database , but their database do n’t admit survivors . They do n’t present such a granularity of multi - omics datum ( unmarried cell and spacial ) , and they lack ethnic diversity . ”
He also claims companies like Flat Iron ( Roche ) , Market Scan ( IBM ) and Iqvia declare oneself “ simple databases with clinical datum and sparse genomic data . ” But molecular databases “ at multi - omics levels are required for drug find , ” he said .
In a statement , Simon Turner , a partner at Sofinnova Partners , commented : “ await at ‘ mechanism of special survival of the fittest ’ is not a novel concept , but Cure51 has taken this to a whole new storey in footing of the scale of the endeavour , plus leverage the latest in analytical techniques . ”
Join us at TechCrunch Sessions: AI
Exhibit at TechCrunch Sessions: AI
The technical school industry has more and more turned its guns on malignant neoplastic disease in recent years .
Alphabetrecentlyannounced a figure of enterprisingness to deploy AI models in the health care diligence . One will be a prick that will help Fitbit exploiter get insights from their devices and a partnership to meliorate screening for genus Cancer and disease in India .
